307 related articles for article (PubMed ID: 32377852)
1. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Karakas D; Ozpolat B
J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
[TBL] [Abstract][Full Text] [Related]
2. Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
Zhu H; Yang X; Liu J; Zhou L; Zhang C; Xu L; Qin Q; Zhan L; Lu J; Cheng H; Sun X
Cell Stress Chaperones; 2015 Mar; 20(2):217-20. PubMed ID: 25248493
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Liu R; Proud CG
Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
[TBL] [Abstract][Full Text] [Related]
4. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
Fu LL; Xie T; Zhang SY; Liu B
Apoptosis; 2014 Oct; 19(10):1527-31. PubMed ID: 25023961
[TBL] [Abstract][Full Text] [Related]
5. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
8. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
Zhou Y; Li Y; Xu S; Lu J; Zhu Z; Chen S; Tan Y; He P; Xu J; Proud CG; Xie J; Shen K
Int J Cancer; 2020 Mar; 146(5):1383-1395. PubMed ID: 31286509
[TBL] [Abstract][Full Text] [Related]
10. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K.
Gurbuz N; Kahraman N; Sonmez HE; Mokhlis HA; Kosar PA; Ozpolat B
Anticancer Agents Med Chem; 2022; 22(14):2607-2618. PubMed ID: 35718922
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
13. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
Xie CM; Liu XY; Sham KW; Lai JM; Cheng CH
Autophagy; 2014 Sep; 10(9):1495-508. PubMed ID: 24955726
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.
Xie J; Mikolajek H; Pigott CR; Hooper KJ; Mellows T; Moore CE; Mohammed H; Werner JM; Thomas GJ; Proud CG
Mol Cell Biol; 2015 May; 35(10):1805-24. PubMed ID: 25776553
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
16. Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.
Wang X; Regufe da Mota S; Liu R; Moore CE; Xie J; Lanucara F; Agarwala U; Pyr Dit Ruys S; Vertommen D; Rider MH; Eyers CE; Proud CG
Mol Cell Biol; 2014 Nov; 34(22):4088-103. PubMed ID: 25182533
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
Xie J; Shen K; Lenchine RV; Gethings LA; Trim PJ; Snel MF; Zhou Y; Kenney JW; Kamei M; Kochetkova M; Wang X; Proud CG
Int J Cancer; 2018 May; 142(9):1865-1877. PubMed ID: 29235102
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.
Kenney JW; Moore CE; Wang X; Proud CG
Adv Biol Regul; 2014 May; 55():15-27. PubMed ID: 24853390
[TBL] [Abstract][Full Text] [Related]
19. Elongation factor eEF2 kinase and autophagy jointly promote survival of cancer cells.
Lenchine RV; Rao SR; Wang X; Fang DM; Proud CG
Biochem J; 2021 Apr; 478(8):1547-1569. PubMed ID: 33779695
[TBL] [Abstract][Full Text] [Related]
20. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
